Journal of Diagnostic Techniques and Biomedical AnalysisISSN: 2469-5653

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Cytoplasmic Expression of P16 is Related to Low Infiltration of CD8+ T cell and Poor Prognosis in Digestive Neuroendocrine Carcinoma

Background and Aims: The aim of this study is to examine the predictive and prognostic value of cytoplasmic P16Ink4A (cP16) and poor infiltration of CD8+ T cell in primary digestive neuroendocrine carcinoma (dNEC). Methods: We retrospectively reviewed 86 cases of NEC and mixed NEC (all cases thereafter refer to NEC), which had primary sites in digestive system. Kaplan-Meier survival curves and log-rank test were used for the survival analysis. Bioinformatics analysis was performed to identify the P16-related pathways. Results: The expression frequency of P16 in dNEC and adjacent tissues was 81.4% and 19.3% respectively (p<0.0001). There was no difference in overall survival (OS) between dNEC patients with P16 positive or negative expression. However, there was a statistically lower OS in dNEC patients with cP16 expression than those without cP16 expression (p=0.050). In addition, cP16 expression was correlated with poor infiltration of intratumoral CD8+ T cells. Furthermore,we found that dNEC patients with two features of cP16 expression in tumor and poor infiltration of CD8+ T cells in intratumoral tissue showed more poor survival (p=0.0133) than patients with single feature alone respectively. Bioinformatics analysis suggested that EGR1 and HLA class I might be involved in the inhibitory effect of cP16 on intratumoral infiltrated T cells. Conclusions: Therefore, the cP16 and poor intratumoral infiltration of CD8+ T cells may serve as poor prognostic biomarkers in dNEC. CP16 expression is associated with decreased intratumoral infiltration of CD8+ T cells probably related to deregulation of EGR1/ HLA class I pathway.

Special Features

Full Text


Track Your Manuscript

Media Partners